Medtronic to acquire SPR Therapeutics for $650m

Medtronic is set to acquire SPR Therapeutics for an upfront cash payment of nearly $650m, expanding care options for individuals with chronic pain. The acquisition enhances Medtronic’s access to peripheral nerve stimulation. By incorporating SPR’s PNS device, Medtronic intends to support medical professionals providing earlier intervention along the chronic pain pathway. Credit: JHVEPhoto / Shutterstock.com. Medtronic is to acquire SPR Therapeutics for an upfront cash payment of nearly $650m, expanding care options for individuals with chronic pain. The company intends to take over all outstanding equity in SPR Therapeutics, which specialises in temporary, percutaneous peripheral nerve stimulation (PNS) therapies designed…

Source: Medical Device Network